A compounding pharmaceutical machine that quietly prints 20%+ profit growth every year

SECTION I — Investment Thesis & Summary

A compounding pharmaceutical machine that quietly prints 20%+ profit growth every year has been sold off nearly 30% from its highs — and the market’s punishing it far more than the fundamentals deserve.

This company does something most Indian pharma companies won’t touch — it goes deep into Latin America and Francophone Africa, markets where global giants don’t bother, competition is thin, and margins are fat. That first-mover advantage isn’t something you can buy with money. It took 20 years to build. And now, with a US business gathering steam and a balance sheet with near-zero debt, this looks like one of the cleaner setups in mid-cap pharma right now.